Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thalidomide + pirarubicin + dexamethasone
- Development stage
- Unknown
- Lead developer
- Grünenthal
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy regimen consisting of thalidomide (an immunomodulatory drug with anti-angiogenic properties), pirarubicin (an anthracycline antibiotic), and dexamethasone (a corticosteroid). While thalidomide + dexamethasone is a well-established combination for multiple myeloma treatment, the specific addition of pirarubicin to this regimen is not well-documented in the provided information.
02
Targets
TOP2A (DNA topoisomerase II)CRBN (Cereblon)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on thalidomide + pirarubicin + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thalidomide + pirarubicin + dexamethasone.